Gleymer David Morelo Espitia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gleymer David Morelo Espitia has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Arturo Vivas Chacon
Universidad de La Sabana
1 shared publication - Claudia Patricia Salas Navarro
Universidad Metropolitana
1 shared publication - Héctor Andrés Guerra Romero
Universidad Surcolombiana
1 shared publication - Juan Camilo Tobón Restrepo
Investigador Independiente
1 shared publication - Luis Mateus Urrutia Osorio
Médico epidemiólogo, Davita SAS, Caucasia
1 shared publication - Said Antonio Durante Furnieles
Universidad del Sinú - Elías Bechara Zainúm
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by Editorial Ibero Ciencias in Ibero Ciencias - Revista Científica y Académica
- Vol. 5 (1) , 409-416
La Precisión Glucocorticoidea en la era de la Medicina Personalizada: Una Revisión Sistemática y Consenso Multidisciplinario Sobre Farmacodinamia, Optimización de Dosis y Estrategias de Seguridad (2025)
More than seventy years after their discovery, the administration of systemic glucocorticoids remains one of the most ubiquitous and decisive interventions in both hospital and outpatient medicine. However, their use has historically been governed by empirical paradigms that prioritized absolute immunosuppression over metabolic preservation. In 2025, a doctrinal shift grounded in molecular biology is underway, marked by the recognition of a “genomic efficacy ceiling” and the dissociation between therapeutic and toxic effects. This comprehensive review synthesizes current evidence derived from pivotal trials such as PEXIVAS and from clinical guidelines issued by KDIGO, ACR, and EULAR (2024), in order to propose a new standard of care. The pharmacological futility of massive oral doses due to receptor saturation is discussed, pulse therapy is redefined toward reduced-dose regimens to minimize infectious risk, and precise endocrinological algorithms are established for the management of the hypothalamic–pituitary–adrenal axis during drug withdrawal. Finally, the mandatory implementation of a prophylactic “safety package” is proposed as an unavoidable ethical requirement in contemporary prescribing practice.
- 16 January 2026
- Published by Editorial Ibero Ciencias in Ibero Ciencias - Revista Científica y Académica
- Vol. 5 (1) , 409-416
Open AccessLa Precisión Glucocorticoidea en la era de la Medicina Personalizada: Una Revisión Sistemática y Consenso Multidisciplinario Sobre Farmacodinamia, Optimización de Dosis y Estrategias de Seguridad (2025)
More than seventy years after their discovery, the administration of systemic glucocorticoids remains one of the most ubiquitous and decisive interventions in both hospital and outpatient medicine. However, their use has historically been governed by empirical paradigms that prioritized absolute immunosuppression over metabolic preservation. In 2025, a doctrinal shift grounded in molecular biology is underway, marked by the recognition of a “genomic efficacy ceiling” and the dissociation between therapeutic and toxic effects. This comprehensive review synthesizes current evidence derived from pivotal trials such as PEXIVAS and from clinical guidelines issued by KDIGO, ACR, and EULAR (2024), in order to propose a new standard of care. The pharmacological futility of massive oral doses due to receptor saturation is discussed, pulse therapy is redefined toward reduced-dose regimens to minimize infectious risk, and precise endocrinological algorithms are established for the management of the hypothalamic–pituitary–adrenal axis during drug withdrawal. Finally, the mandatory implementation of a prophylactic “safety package” is proposed as an unavoidable ethical requirement in contemporary prescribing practice.